Abstract:
Postpartum haemorrhage is the leading cause of maternal mortality worldwide, killing a mother every 7 minutes. As with any major haemorrhage, it is the ticking clock that often kills women. Delays in diagnosis, delays in treatment, and delays in escalation of care could result in time – and lives – lost. There is a simple innovation that can help with early and accurate diagnosis of postpartum haemorrhage. There is a bundle of care that can ensure all effective treatments are provided to all those who need it. A cluster randomised trial incorporating the diagnostic innovation and bundled treatment for postpartum haemorrhage, published recently in the NEJM, has found an incredible 60% reduction in women suffering severe postpartum haemorrhage, needing surgery or dying from bleeding. This has been hailed as a breakthrough. Attend this lecture to find out more.

Bio:
Professor of Gynaecology and Reproductive Medicine at University of Birmingham, Director of the Tommy’s National Centre for Miscarriage Research and Founding Director of the WHO Collaborating Centre for Global Women’s Health.
Professor Coomarasamy leads two research teams, one focusing on treatments to prevent miscarriages and the other targeting on ways to stop mothers dying during childbirth. Professor Coomarasamy’s research portfolio includes numerous national and international multicentre randomised controlled trials, including: The PROMISE Trial (2015), The WHO CHAMPION Trial (2018), The TABLET Trial (2019), The AIMS Trial (2019), The PRISM Trial (2019), The MifeMiso Trial (2020), The E-MOTIVE Trial (2023), and The LOCI Trial (ongoing). Professor Coomarasamy has published over 300 articles in high impact journals such as the New England Journal of Medicine, The Lancet, The British Medical Journal and the Cochrane Database of Systematic Reviews.